EUVIMEDEUVIMED entdecken
Crossref

LONG-ACTING INJECTABLE ANTIPSYCHOTICS IN SCHIZOPHRENIA

Juan José Beloqui, María Sánchez, Virginia Basterra

Boletín de Información Farmacoterapéutica de Navarra · 2023

DOI: 10.54095/bitn20233101en ↗

Kurz gefasst

Fachartikel in der Zeitschrift Boletín de Información Farmacoterapéutica de Navarra, 2023. Verfasst von Juan José Beloqui und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antipsychotics serve as the cornerstone of pharmacological treatment for schizophrenic disorders, including both the management of acute episodes and the prevention of relapse. Longacting injectable antipsychotics (LAIAs) are intended to improve treatment compliance, thereby reducing the risk of relapse and hospitalization. The marketing of LAIAs has increased over the past few years, consequently expanding the range of active substances and extending dosing intervals (bi-weekly, monthly, quarterly and semi-annually). This new situation represents a qualitative change in the available therapeutic approaches for schizophrenia, although a risk/benefit assessment is required, and the prescribing efficiency from an overall patient health perspective needs to be studied.

Zitieren

APA

Beloqui, J. J., Sánchez, M., & Basterra, V. (2023). LONG-ACTING INJECTABLE ANTIPSYCHOTICS IN SCHIZOPHRENIA. Boletín de Información Farmacoterapéutica de Navarra. https://doi.org/10.54095/bitn20233101en

Vancouver

Beloqui JJ, Sánchez M, Basterra V. LONG-ACTING INJECTABLE ANTIPSYCHOTICS IN SCHIZOPHRENIA. Boletín de Información Farmacoterapéutica de Navarra. 2023. doi:10.54095/bitn20233101en

BibTeX
@article{Beloqui2023,
  author = {Beloqui, Juan José and Sánchez, María and Basterra, Virginia},
  title = {LONG-ACTING INJECTABLE ANTIPSYCHOTICS IN SCHIZOPHRENIA},
  journal = {Boletín de Información Farmacoterapéutica de Navarra},
  year = {2023},
  doi = {10.54095/bitn20233101en}
}
Kostenlos starten →